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LETTERS TO THE EDITOR
Peripheral blood
myeloperoxidase activity
increases during hemodialysis
To the Editor: In their paper, Pecoits-Filho et al [1]
show that a higher expression polymorphism in the pro-
moter region of myeloperoxidase (MPO) is associated with
cardiovascular disease in end-stage renal disease (ESRD)
patients. We have data that show that not only a genetic
polymorphism can result in higher MPO expression, but
that dialysis itself can also contribute to an increased MPO
activity. For this purpose, we measured the change in
neutrophil MPO activity (delta MPXI) pre- and postdial-
ysis in 54 patients and at a 4-hour interval in 12 healthy
control patients using an automated hematologic ana-
lyzer (ADVIA 120; Bayer, Tarrytown, NY, USA) [2].
Patients were dialyzed with polyamide or polysulfone
membranes using ultrapure dialysate. For comparison
between the two groups, nonparametric t testing was
performed. Bars represent the average change in MPXI
per group; error bars indicate 95% confidence intervals.
Thus, we found that dialysis, even with the use of bio-
compatible membranes and ultrapure dialysate, contrib-
utes to an increase of neutrophil MPO activity. Interest-
ingly, elevated levels of MPO are associated with the
presence of atherosclerosis [3], and increased MPO activity
can contribute to the proatherosclerotic actions of MPO,
including oxidation of low-density lipoprotein (LDL) and
consumption of nitric oxide [3].
Future studies should elucidate the role of increased
MPO activity in accelerated atherosclerosis of dialysis
patients.
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Albuminuria and renal
insufficiency prevalence
guides population screening
To the Editor: Garg et al [1] present the prevalence
of albuminuria and renal insufficiency from the National
Health and Nutrition Examination Survey (NHANES) III
between 1988 and 1994 as a guide to the number needed
to screen when considering early intervention to prevent
end-stage renal disease. The authors discuss the effects of
prescribing practices on such calculations, but analysis of
such effects was avoided due to the survey predating the
publication of studies demonstrating the efficacy of antihy-
pertensive therapy. The Australian Diabetes, Obesity and
Lifestyle Study, a population-representative study of 11,247
Australian adults was undertaken between 1999 and 2000,
and can provide some insights into the effect of current
use of antihypertensive therapy on the determination of
number needed to screen for albuminuria (Table 1) [2].
The prevalence of urine albumin to creatinine ratio 3.0
mg/mmol was significantly lower in the Australian survey
compared to NHANES III, except in the nondiabetic hy-
pertensive subgroup. Of individuals with albuminuria, lack
of antihypertensive therapy was reported in 61% overall:
48% of the diabetic subgroup, 41% of the nondiabetic,
hypertensive subgroup, and 100% of the nondiabetic,
nonhypertensive subgroup. The prevalence of albumin-
uria for all subgroups was significantly lower among indi-
